Leuject (Cladribine)

Cladribine is taken up by lymphocytes and phosphorylated to an active triphosphate that incorporates into DNA. This incorporation causes DNA strand breaks, leading to programmed cell death (apoptosis) of the targeted immune cells, thereby reducing disease‑driving lymphocyte populations.

The dose of Leuject is determined individually by the prescribing physician based on the specific indication, patient characteristics, and clinical response. Exact dosing regimens are not disclosed here and should follow the prescriber’s instructions.

Safety data for cladribine during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit outweighs the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and for the period recommended by their healthcare provider.

To place an order, submit an enquiry on the Leuject product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Leuject (cladribine) belongs to the purine nucleoside analog class, offering a distinct mechanism compared with agents like fludarabine or monoclonal antibodies. In multiple sclerosis, cladribine provides an oral‑or‑injectable option with intermittent dosing, whereas many alternatives require continuous administration. Choice of therapy depends on efficacy, safety profile, patient preference, and physician assessment.

Leuject should be stored at 2 °C to 8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not store at ambient temperature, as temperature excursions may affect product stability.

Leuject is supplied for subcutaneous injection. The vial is typically reconstituted with a suitable diluent according to the manufacturer’s instructions, and the prepared solution is injected into the subcutaneous tissue by a qualified healthcare professional using aseptic technique.

The most serious risks include severe lymphopenia leading to opportunistic infections, autoimmune hemolytic anemia, secondary malignancies, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of infection, blood count changes, and any unusual skin or systemic symptoms.

Leuject is contraindicated in patients with active severe infections, known hypersensitivity to cladribine or any excipients, and those who are pregnant or breastfeeding unless the benefit justifies the risk. Caution is also advised for individuals with severe renal impairment or uncontrolled autoimmune disorders.